XSTO
MCOVb
Market cap3.94bUSD
Oct 09, Last price
263.50SEK
1D
1.35%
1Q
14.57%
IPO
313.33%
Name
Medicover AB
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1995 and headquartered in Stockholm, Sweden, Medicover AB (publ) is a prominent international provider of both healthcare and diagnostic services. The company operates across numerous countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It is structured into two main divisions: Healthcare Services and Diagnostic Services. Through its diagnostic division, Medicover performs a comprehensive array of specialized tests, which include analyses for allergy and autoimmune conditions; bacteriology and parasitology; biochemistry and immunochemistry; blood group diagnostics and transfusion medicine; tumour markers; clinical chemistry; cellular analyses like cytology, haematology, and histopathology; human genetics; hygiene; general immunology; infectious diseases; microbiology; molecular biology; and pharmacology/toxicology. Medicover maintains a substantial operational footprint, encompassing 97 clinical laboratories, 733 blood-drawing points, and 26 clinics dedicated to diagnostic services across 10 countries. Its healthcare segment further comprises 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. The company caters to a broad customer base, serving corporate entities, private individuals, direct patients, and public sector payers.
Related entities
Parent (2)
Celox Holding AB
Jonas and Christina af Jochnick Foundation
Subsidiaries (4)
ABC Medicover Holdings B.V.
BELRO MEDICAL
MEDICOVER HOLDING S.A.
Medicover Investment B.V.
Key people
Fredrik Stenmo
Chairman of the Board · since 2017
John Stubbington
Chief Executive Officer · since 2025
Anand Patel
Chief Financial Officer · since 2024
Kamila Skorupinska
Chief People Officer · since 2024
Jaroslaw Urbanczyk
Chief Information Officer · since 2019
Andrew Vallance-Owen
Chief Marketing Officer · since 2017
Jenny Brandt
General Legal Counsel
Lukasz Krause
Chief Digital Information Officer · since 2025
Staffan Ternstroem
Chief Operating Officer, Diagnostic Services · since 2021
Peder af Jochnick
Director · since 2012
Fredrik Ragmark
Director · since 2025
Anne-Catherine Berner
Independent Director · since 2022
Arno Bohn
Independent Director · since 2001
Independent Director · since 2017
Independent Director · since 2015
Margareta Nordenvall
Independent Director · since 2001
Claudia Olsson
Independent Director · since 2025
Azita Shariati
Independent Director · since 2022
Headquarters & legal address
P.O. Box 5283
Stockholm, AB 102 46
SE
Stockholm, AB 102 46
SE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||